Drug Discovery World

MARCH 14, 2023

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest.

Disease 130

Disease Treatment Science Clinical Development 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Target Review

OCTOBER 5, 2023

This innovative approach involves the extraction of a patient’s own stem cells from either their bone marrow or blood , followed by a course of chemotherapy and antibody treatment. The research team identified 231 individuals diagnosed with relapsing-remitting MS, with 174 of them having undergone aHSCT treatment before the year 2020.

Therapies 116

Therapies Treatment Clinical Trials Disease 116

Drug Discovery World

APRIL 3, 2024

While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types 1.

Targeted Protein Degradation 130

Targeted Protein Degradation Research Therapies Drugs 130

Drug Target Review

JUNE 8, 2023

An important research area at AbbVie involves blood cancers, where our ultimate goal is to transform standards of care across these diseases and advance a dynamic cancer research and treatment pipeline. 2 However, treatment options were still limited and often came with severe side effects.

Treatment 105

Treatment Organic Chemistry Research Disease 105

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Drug Discovery World

MAY 3, 2024

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).

Disease 130

Disease Therapies Trials Treatment 130

Drug Target Review

NOVEMBER 7, 2023

Chemists at Stanford University discovered how one of the pathways leading to this protein “woodchipper” works furthering the understanding of new therapeutics for autoimmune diseases, age-related disorders, and treatment-resistant cancers. Enzyme replacement therapy is a frequent treatment for these disorders.

Therapies 59

Therapies Science Disease Treatment 59

The Pharma Data

DECEMBER 8, 2020

Blood disease trial participants given Vertex’s and CRISPR Therapeutics’ CRISPR/Cas9-based gene-editing therapy CTX001 demonstrated a “consistent and sustained response” to the treatment, according to new phase 1/2 trial data the companies have announced. To date, a total of 19 trial participants have been dosed with the gene therapy.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 18, 2020

Over the past decade, the world has witnessed unprecedented scale-up of antiretroviral therapy (ART), which has saved the lives of tens of millions of people. Standardized surveillance of HIV drug resistance provides countries with actionable evidence that is used to optimize patient and population-level treatment outcomes. infants.

Laboratories 52

Laboratories Virus Government Therapies 52

The Pharma Data

APRIL 7, 2022

This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM ® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Treatment 52

Treatment Therapies Disease FDA Approval 52

The Pharma Data

NOVEMBER 3, 2020

4, 2020 /PRNewswire/ — Q3 2020 highlights. m (-), including US launch of the scientifically proven digital therapies deprexis® and vorvida®. Updated financial outlook 2020. 2020 Jul-Sep. 2020 Jan-Sep. m (90.9).

Therapies 52

Therapies Pharmaceuticals Production Marketing 52

Drug Discovery World

MARCH 10, 2023

The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In In China, the incidence rate of bladder cancer in 2020 ranked 12th among all cancers, with an estimated 85,649 new cases that year.

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

FDA 72

FDA Vaccine Drugs Therapies 72

The Pharma Data

NOVEMBER 30, 2020

The UK-based RECOVERY trial, which is evaluating multiple treatments for COVID-19, will add the inexpensive anti-inflammatory drug colchicine to the list of therapies being tested in hospitalized patients.

Treatment 52

Treatment Trials Hospitals Therapies 52

Drug Discovery World

MAY 29, 2023

When it comes to published scientific research, the UK is ranked third in the world with nearly 200,000 citable publications in 2020. The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone.

Therapies 130

Therapies Science Trials Production 130

The Pharma Data

NOVEMBER 18, 2020

-based Obsidian Therapeutics and the University of Texas’ MD Anderson Cancer Center have forged a multi-year deal to develop tumor-infiltrating lymphocytes (TILs) as a treatment for solid tumors. Source link.

Therapies 52

Therapies Treatment Disease Research 52

The Pharma Data

NOVEMBER 8, 2020

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. LONDON and RALEIGH, N.C.,

Therapies 52

Therapies Treatment Disease Hospitals 52

Drug Discovery World

NOVEMBER 30, 2023

Working with cell lines from a patient whose glioblastoma returned after prior treatments, the team used CRISPR to destroy the tumour cells while sparing healthy cells. Glioblastoma is the most common lethal brain cancer, and patients still don’t have any good treatment options,” says Christof Fellmann, who led the study at Gladstone.

DNA 147

DNA Treatment Regulations Therapies 147

The Pharma Data

NOVEMBER 25, 2020

AHA: Ablation Better Than Meds for Initial A-Fib Treatment. 25, 2020 — Cryoballoon ablation is superior to drug therapy as an initial treatment for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation , according to a study published online Nov. © 2020 HealthDay.

Treatment 52

Treatment Therapies Disease Drugs 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. BUFFALO, N.Y., Founded in 2003, Athenex, Inc.

Engineering 52

Engineering Therapies International Treatment 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. Nestlé Health Science has a history of advancing nutritional therapies.

Science 52

Science Pharmaceuticals Disease FDA Approval 52

The Pharma Data

MARCH 9, 2022

Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells. Although still in the early stages, the findings open the possibility of having a new therapy for COVID-19 patients.

Treatment 52

Treatment Virus Engineering Therapies 52

The Pharma Data

DECEMBER 29, 2020

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN. 29, 2020 — Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

Treatment 52

Treatment International Therapies Research 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Therapies 52

Therapies FDA Clinical Trials Production 52

The Pharma Data

JANUARY 12, 2021

Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the full year 2020 is expected to be approximately $125.4 2020 was a transformational year for Vapotherm.

Production 52

Production Therapies Marketing Regulations 52

The Pharma Data

OCTOBER 22, 2020

CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy. Source link.

Treatment 40

Treatment Therapies Trials Pharmaceuticals 40

The Pharma Data

SEPTEMBER 21, 2020

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Therapies 52

Therapies Treatment Disease 52

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. © 2020 HealthDay. Posted: December 2020. MONDAY, Dec. More Information.

FDA Approval 52

FDA Approval Therapies FDA Science 52

The Pharma Data

SEPTEMBER 1, 2020

Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for the management of low-density lipoprotein cholesterol (LDL-C) when added to other standards of care. compared to placebo on top of maximally tolerated statin therapy and other LLTs throughout the 78 weeks.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

The Pharma Data

MARCH 24, 2021

billion EUR in 2020 (18.9% Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. In particular, efforts to research potential COVID-19 related therapies were accelerated.

Vaccine 52

Vaccine Small Molecule Therapies Disease 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. In addition, health-related quality of life (HRQoL), per total Functional Assessment of Cancer Therapy–Prostate (FACT-P), continued to be maintained with ERLEADA ®.

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

NOVEMBER 20, 2020

20, 2020 — Hormone therapy can be a lifesaver for men with prostate cancer , but it also appears to put some at increased risk of heart problems, a new study reports. “We need to do everything we can to ensure the patients can receive lifesaving cancer therapy in a safe manner,” Ky said. FRIDAY, Nov.

Therapies 52

Therapies Doctors Disease Hospitals 52

The Pharma Data

OCTOBER 19, 2020

Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients. 19, 2020 — For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published online Oct. Professional.

Therapies 52

Therapies Treatment Pharmaceuticals Disease 52

The Pharma Data

SEPTEMBER 24, 2020

NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328 th consecutive quarterly dividend paid by Pfizer. Pfizer Inc.:

Government 40

Government Vaccine Science Therapies 40